Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Rybak

Showing results (311-320 of 531) with videos related to

Pageof 54
Sort By:
Antimicrobial Agents and Chemotherapy|June 1, 1992
CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditisG W Kaatz, S M Seo, K C Lamp, et al.
The Journal of Antimicrobial Chemotherapy|December 15, 2007
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosaJudy N Chin, Ronald N Jones, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1990
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditisG W Kaatz, S M Seo, V N Reddy, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2008
Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic modelWarren E Rose, Steven N Leonard, Kerri L Rossi, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1989
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditisG W Kaatz, S M Seo, S L Barriere, et al.
Gastroenterology|November 1, 1972
Ultrastructural changes in the small intestine induced by ethanolE Rubin, B J Rybak, J Lindenbaum, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic modelBrian J Werth, George Sakoulas, Warren E Rose, et al.
International Journal of Psychiatry in Clinical Practice|June 20, 2014
Clozapine response in early treatment-resistant schizophreniaG Joffe, J Rybak, M Burkin, et al.
Infectious Diseases and Therapy|August 3, 2020
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the HorseTaylor Morrisette, Thomas P Lodise, Marc H Scheetz, et al.
European Journal of Medicinal Chemistry|March 13, 2012
Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agentsMahender B Dewal, Amit S Wani, Celine Vidaillac, et al.
Pageof 54

Showing results (311-320 of 531) with videos related to

Sort By:
Pageof 54
Antimicrobial Agents and Chemotherapy|June 1, 1992
CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditisG W Kaatz, S M Seo, K C Lamp, et al.
The Journal of Antimicrobial Chemotherapy|December 15, 2007
Potential synergy activity of the novel ceragenin, CSA-13, against clinical isolates of Pseudomonas aeruginosa, including multidrug-resistant P. aeruginosaJudy N Chin, Ronald N Jones, Helio S Sader, et al.
Antimicrobial Agents and Chemotherapy|November 1, 1990
Daptomycin compared with teicoplanin and vancomycin for therapy of experimental Staphylococcus aureus endocarditisG W Kaatz, S M Seo, V N Reddy, et al.
Antimicrobial Agents and Chemotherapy|November 19, 2008
Impact of inoculum size and heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) on vancomycin activity and emergence of VISA in an in vitro pharmacodynamic modelWarren E Rose, Steven N Leonard, Kerri L Rossi, et al.
Antimicrobial Agents and Chemotherapy|August 1, 1989
Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditisG W Kaatz, S M Seo, S L Barriere, et al.
Gastroenterology|November 1, 1972
Ultrastructural changes in the small intestine induced by ethanolE Rubin, B J Rybak, J Lindenbaum, et al.
Antimicrobial Agents and Chemotherapy|October 17, 2012
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic modelBrian J Werth, George Sakoulas, Warren E Rose, et al.
International Journal of Psychiatry in Clinical Practice|June 20, 2014
Clozapine response in early treatment-resistant schizophreniaG Joffe, J Rybak, M Burkin, et al.
Infectious Diseases and Therapy|August 3, 2020
The Pharmacokinetic and Pharmacodynamic Properties of Hydroxychloroquine and Dose Selection for COVID-19: Putting the Cart Before the HorseTaylor Morrisette, Thomas P Lodise, Marc H Scheetz, et al.
European Journal of Medicinal Chemistry|March 13, 2012
Thieno[2,3-d]pyrimidinedione derivatives as antibacterial agentsMahender B Dewal, Amit S Wani, Celine Vidaillac, et al.
Pageof 54